16
Mar
2017
eGenesis Snags $38M to Make CRISPR-modified Pigs for Organ Transplantation
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Mar
2017
Biomatics, Run by Gates Vets, Raises $200M for Genomics & Healthcare Startups
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Mar
2017
Gottlieb on Deck at FDA, Editing Human Embryos, & Gilead Exec Rips PBMs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Mar
2017
Dunsire Joins Xtuit to Fight Microenvironment; Spero Gets $51.7M for Antibiotics
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Mar
2017
Grail’s $900M Haul, Kite’s CAR-T Stands Up 6 Months, & Icahn Returns
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Feb
2017
The Aconcagua Expedition Photos
It was cold enough that my ridiculously fluffy 8,000-meter-rated goose down parka was a must-wear. Wind gusts knocked me off my feet once, and kept the tent flapping all night long. Mountain air was so bone-dry, my boogers turned into gravelly nuggets. Tolerance for grime was a must, given that we were wearing the same sweat-encrusted socks and underwear every day. Sleeping... Read More
27
Feb
2017
You Can’t Do That With RNA, Can You? Arrakis Tests Small Molecules in a New Way
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Feb
2017
BMS on the Block (Maybe), Sarepta Sells a Golden Ticket to Gilead & a Summit Pic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Feb
2017
Join Me at BIO-Europe Spring Mar. 21 in Barcelona To Talk EU Entrepreneurship
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Jan
2017
J&J Reels in Actelion for $30B, Celgene Snaps up Delinia, and an IPO Flurry
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Jan
2017
Women Making Progress, Very Slowly, On Biotech Boards, Report Says
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Jan
2017
Who’s In and Out on Trump’s Health Team, BMS Cedes Ground to Merck, & CRE Superbugs on the Move
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Jan
2017
Takeda Leans on a Little Guy, Ovid Therapeutics, to Go the Distance With an Epilepsy Drug
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Jan
2017
Takeda Takes Out Ariad, Illumina Plants a $100 Genome Stake, & Anti-Vaxxer Nuzzles With Trump
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Jan
2017
Amgen Wins PCSK9 Duel, Jenkins’ Parting Shot, and Obamacare’s Last Stand
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Jan
2017
Neon Therapeutics Gets $70M to Push Neoantigen Cancer Vaccines
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Dec
2016
Big RNA Day For Spinraza, Cempra Stumbles, and Intarcia Rakes in More Loot
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Dec
2016
Senators Dial Up the Heat, the Overblown CRISPR Case, & Biogen’s New CEO
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Dec
2016
Unfashionable Science, and a Daring Model for Alzheimer’s, Without VCs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Dec
2016
Merck Thumps Gilead in Court, Genentech’s New CEO, Alexion Turmoil
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.